Treatment of lupus nephritis with cyclophosphamide.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D001379:Azathioprine / Q000627:therapeutic use; D001706:Biopsy; D002699:Chlorambucil / Q000627:therapeutic use; D003348:Cortisone / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D007668:Kidney / Q000473:pathology; D007970:Leukopenia / Q000139:chemically induced; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008466:Mechlorethamine / Q000627:therapeutic use; D015122:Mercaptopurine / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D011507:Proteinuria / Q000209:etiology; D044469:Racial Groups; D012709:Serum Albumin / Q000032:analysis; D012737:Sex Factors; D013866:Thioguanine / Q000627:therapeutic use
D012709:Serum Albumin; D002699:Chlorambucil; D008466:Mechlorethamine; D003520:Cyclophosphamide; D011239:Prednisolone; D015122:Mercaptopurine; D013866:Thioguanine; D001379:Azathioprine; D003348:Cortisone